Slide 1: 2024 Full Year Results
2024 FULL YEAR RESULTS SUSTAINABLE INNOVATION, WORLD-CLASS SURGEON EDUCATION, AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES 25 March 2025
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Medacta environment in which the Group operates; manufacturing or logistics Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or disruptions; the impact of fluctuations in foreign exchange rates; and the “Group”)
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer
Slide 4: Highlights - 2024 Full Year Results
Highlights - 2024 Full Year Results FY 2024 revenue in EUR Adjusted EBITDA margin** 590.6 m 28.0 % in cc * 16.2 % growth in cc* 27.1 % in EUR Adj. EBITDA of EUR 160.2 m Record net profit of EUR 72.9 m Proposed dividend of CHF 0.69 per share rise of 19.4% over 2023, or increase of 53.9% over 2023, or
Slide 5: Considerable above market revenue growth
Considerable above market revenue growth • 2024 revenue growth* of 16.2% Group revenue CAGR* (2020-2024): yoy 18.1% • Revenue CAGR* (2020-2024) of 600 18.1% 500 • Considerable above market revenue growth as result of 400 • Out-of-the-box thinking EUR m 300 innovations to improve patient outcome and
Slide 6: Outstanding growth across all geographies
Outstanding growth across all geographies FY 2024 geographic revenue distribution 16.2%* LATAM EUR 12.4m, 15.1 2.3 593.6 590.6 2% 25.4 40.0 510.8 -3.0 APAC EUR 115.1m, EUR m 20% EMEA 16.5% 16.5% 14.5% 22.5% EUR 283.7m, NA Growth rate in constant currency 48% EUR 179.3m, 30% FY 2023 EMEA NA LATAM FY
Slide 7: Clear market outperformance across all business lines
Clear market outperformance across all business lines FY 2024 revenue distribution by business line 16.2%* Spine 43.4 14.1 6.2 593.6 590.6 EUR 51.8m, 510.8 19.0 Extremities -3.0 9% EUR 50.3m, 8% Hip, EUR m EUR 247.3m, 42% 8.3% 21.9% 38.8% 13.4% Knee Growth rate in constant currency EUR 241.2m, 41% 7
Slide 8: Solid growth in Hip
Solid growth in Hip Hip Revenue CAGR* (2020-2024): 12.8% 250 200 EUR m 150 100 50 0 2020 2021 2022 2023 2024 Hip • Growth mainly attributable to Medacta’s Anterior Minimally Invasive Surgery (AMIS) platform • > 2 times market outperformance 2024E** yoy 8 Notes * in constant currency ** THE ORTHOPAED
Slide 9: Notable expansion in Knee
Notable expansion in Knee Knee Revenue CAGR* (2020-2024): 22.1% 250 200 EUR m 150 100 50 0 2020 2021 2022 2023 2024 Knee • Outstanding performance due to Medacta’s personalised Kinematic Alignment platform MyKA and GMK SpheriKA • Robust growth across all geographic regions • > 3 times market outperf
Slide 10: Outstanding growth in Spine
Outstanding growth in Spine Spine Revenue CAGR* (2020-2024): 17.1% 60 50 40 EUR m 30 20 10 0 2020 2021 2022 2023 2024 Spine Selection of pre-contoured rods • Solid revenue acceleration strongly supported by Medacta’s technologies, particularly by NextAR Spine • Particularly strong performance in EME
Slide 11: Continued superior growth in Extremities
Continued superior growth in Extremities Extremities Revenue CAGR* (2020-2024): 36.5% 60 50 40 EUR m 30 20 10 0 2020 2021 2022 2023 2024 Extremities • Expansion primarily due to Medacta’s Shoulder System, supported by advanced technologies such as MyShoulder and NextAR • Sportsmed still small, but g
Slide 12: Sustainability highlights 2024
Sustainability highlights 2024 100% 97% 98% 100% renewable electricity of new supplier of employees trained on rate of return used at Medacta’s evaluated health & safety matters after maternal leave production sites according to ESG indicators 12
Slide 13: Further advancements in sustainability
Further advancements in sustainability Caring for the environment Ensure responsible supply Caring for People Caring for Community chain - 43.8% of greenhouse gas - Continuous professional - Medacta for Life Foundation emission* reduction - Safeguarding responsible development initiatives supporting
Slide 14: Our commitments
Our commitments Adoption of Task Force on Climate-related Financial Disclosures in accordance with art. 3 of the Swiss Ordinance on Climate Disclosures and complying to Swiss Code of Obligation art. 964 Adoption of United Nation’s Sustainable Development Goals 14
Slide 15: Corrado Farsetta, Chief Finance Officer
Corrado Farsetta Chief Finance Officer
Slide 16: Gross profit rising by approx. 15%
Gross profit rising by approx. 15% 450 399.4 400 • Gross profit of EUR 399.4 m vs. EUR 350 347.8 347.8 m in 2023, an increase of 14.8% yoy Gross profit in EUR m 300 250 • Gross profit margin was 67.6% 200 compared to 68.1% in 2023; the 150 softening was largely due to the negative translational FX i
Slide 17: Adj. EBITDA margin rising to 28.0%
Adj. EBITDA margin rising to 28.0% * Adj. EBITDA and EBITDA margin in cc* continue to increase • Adj. EBITDA of EUR 160.2 m compared to EUR 134.2 m in 200 35% 2023, an increase of 19.4% yoy 31.8% 30.3% 30.5% 29.8% 30.1% 28.0% 30% 160 29.5% • Adj. 2024 EBITDA margin of Adj. EBITDA in EUR m 29.1% Adj.
Slide 18: Net profit surging by approx. 54%
Net profit surging by approx. 54% • Profit before tax was EUR 87.8 m compared to EUR 58.7 m in 2023. The increase was mainly attributable due to 80 the better financial results largely 72.9 benefitting from more favourable FX 70 impact 60 Net profit in EUR m 50 47.4 • Effective tax rate of 17.0% vs
Slide 19: CAPEX to drive growth and expansion
CAPEX to drive growth and expansion • Total CAPEX was EUR 98.9 m compared to EUR 80.6 m in 2023, as Medacta Financial investments EUR 1.9 m continues to invest in growth Other intangibles Instruments EUR 2.7 m EUR 57.8 m • Almost 83% of CAPEX was CAPEX related to growth; this includes instruments an
Slide 20: Operating cash flow increasing a good 42%
Operating cash flow increasing a good 42% • Cash flow from operating activities increased by a good 42% to EUR 107.1 m compared to EUR 75.1 m in 2023 (EUR m) • Cash flow from investing activities were EUR 98.9 m vs. EUR 80.6 m in the Cash Flow FY 2024 FY 2023 prior year mainly reflecting investments
Slide 21: Maintaining a strong balance sheet
Maintaining a strong balance sheet Net debt / adj. EBITDA (x) 1.1 1.01 0.99 1 0.95 0.93 0.9 0.87 0.8 • Continued strong balance sheet 0.7 • 2024 net debt / adj. EBITDA was 0.6 0.99x 0.5 • Net debt / adj. EBITDA on 0.4 average at 0.95x over the past five years 0.3 0.2 2020 2021 2022 2023 2024 21 Note
Slide 22: Dividend per share (CHF)
Dividend per share 0.7 0.69 0.6 0.55 0.54 0.54 Dividend per share (CHF) 0.5 • Substantial dividend increase of a 0.4 good 25% over the prior year 0.3 • A dividend of CHF 0.69 per share to be proposed by Board of 0.2 Directors at AGM 2025 on 7 May 2025 0.1 0 2021 2022 2023 2024 22 Notes Definitions o
Slide 23: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer
Slide 24: Outlook
Outlook Outlook 2025 We are targeting a revenue growth in the range of 13% to 15% in constant currency and an adjusted EBITDA margin of around 27% including the recent Parcus acquisition, subject to unforeseen events. Mid-term outlook Revenue compound annual growth rate (CAGR) (2024-2027E) in consta
Slide 25: Key Messages
Key Messages • Significant above-market FY 2024 revenue growth of 16.2% yoy in constant currency as result of • Out-of-the-box thinking innovations to improve patient outcome and healthcare sustainability • Education and personalised training of surgeons • Further expansion of sales reps and team •
Slide 26: Thank you
Thank you to all our employees, clients, suppliers and partners worldwide.
Slide 27: Financial Calendar 2025
Financial Calendar 2025 Date Event Location 26. March Full Year 2024 Roadshow Milan 27. March Full Year 2024 Roadshow Frankfurt 28. March Full Year 2024 Roadshow Paris 31. March Full Year 2024 Roadshow London 01. April Full Year 2024 Roadshow Zurich 07. May AGM Rancate (CH) 31. July H1 2025 Revenue